Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
An FDA advisory committee voted in favor of GRAIL's Galleri multi-cancer early detection (MCED) blood test, saying its benefits outweigh its risks for adults 50 and older. The panel voted unanimously on safety, 6-4 on effectiveness, and 7-2 on benefit-risk balance — but many members flagged the absence of mortality outcome data as a significant concern. FDA approval could unlock Medicare coverage starting in 2028.
An FDA advisory committee has given a thumbs-up to GRAIL's Galleri multi-cancer early detection (MCED) blood test, voting that its benefits outweigh its risks for adults aged 50 and older. The panel voted unanimously (10-0) on safety, 6-4 on effectiveness, and 7-2 (with one abstention) on the benefit-risk balance. The test works by detecting cancer-specific DNA methylation patterns in the blood and can flag signals across more than 50 cancer types — including many for which no standard screening currently exists. It is designed to complement, not replace, guideline-recommended screenings.
Despite the favorable votes, enthusiasm was tempered. Several panelists — even those who voted yes — stressed that no data yet show the test reduces cancer mortality. The landmark NHS-Galleri randomized trial failed to meet its primary endpoint of reducing late-stage cancer diagnoses. Panelists also raised concerns about false reassurance from negative results, potential overuse beyond the approved age group, and downstream strain on already-stretched radiology and endoscopy resources.
By the Numbers:
Why it matters: If the FDA follows the panel's recommendation and approves Galleri, it would be the first FDA-approved MCED test — a potential game-changer for detecting cancers that currently have no screening options. A 2026 law also directs Medicare to cover FDA-approved MCED tests starting in 2028, making this a pivotal moment for both oncology and health policy.
